Adela, Inc.’s Post

Data recently presented at #ASCO24 showed "MRD detection using [Adela's] cfMeDIP-seq platform correlated strongly with reported recurrence-free survival with hazard ratios consistent with what has been described previously for tumor-informed assays." The presentation by Dr. Liu from Princess Margaret Cancer Center reported on data from a Head & Neck cancer study with Adela, Inc. consisting of a training cohort of 130 patients, of which 45 had a recurrence and 85 did not. https://lnkd.in/gp-tgn2R #MRD #NGS #precisiononcology #futureofcancercare